CL
RXRX icon

CSS LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

CSS LLC’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,231
Closed -$92.2K – 1164
2025
Q2 		$92.2K Sell
18,231
-38,208
-68% -$188K ﹤0.01% 845
2025
Q1 		$299K Buy
56,439
+2,346
+4% +$17.1K 0.02% 634
2024
Q4 		$366K Buy
+54,093
New +$364K 0.02% 654

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's RXRX Position: Q3 2025 in Review

CSS LLC sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 18,231 shares — an estimated $92.2K sold.

CSS LLC first reported a position in RXRX in Q4 2024 and held it in 3 quarters. The position peaked at $366K in Q4 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • CSS LLC reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • CSS LLC sold 18,231 Recursion Pharmaceuticals shares in Q3 2025, an estimated $92.2K.
  • CSS LLC first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • CSS LLC's Recursion Pharmaceuticals position peaked at $366K in Q4 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on CSS LLC's 13F filing for Q3 2025, filed 13 Nov 2025.